This topic contains a solution. Click here to go to the answer

Author Question: Marcus is concerned that inflation will erode the purchasing power of the face value of his life ... (Read 73 times)

jho37

  • Hero Member
  • *****
  • Posts: 531
Marcus is concerned that inflation will erode the purchasing power of the face value of his life insurance policy.
 
  His agent suggested that Marcus add a provision that allows him to purchase one-year term insurance equal to the percentage change in the consumer price index without having to demonstrate insurability. This provision is called a(n)
  A) cost-of-living rider.
  B) guaranteed purchase option.
  C) accelerated death benefit rider.
  D) waiver-of-premium rider.

Question 2

Which statement about the incontestable clause is true?
 
  I. It protects the beneficiary if the insurer tries to deny a claim years after the policy is issued.
  II. If protects the insurer from having to pay a claim during the first two years if the insured made a material misrepresentation or concealed material information in the application.
  A) I only
  B) II only
  C) both I and II
  D) neither I nor II



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

alexanderhamilton

  • Sr. Member
  • ****
  • Posts: 334
Answer to Question 1

Answer: A

Answer to Question 2

Answer: C





 

Did you know?

Children of people with alcoholism are more inclined to drink alcohol or use hard drugs. In fact, they are 400 times more likely to use hard drugs than those who do not have a family history of alcohol addiction.

Did you know?

The ratio of hydrogen atoms to oxygen in water (H2O) is 2:1.

Did you know?

Certain topical medications such as clotrimazole and betamethasone are not approved for use in children younger than 12 years of age. They must be used very cautiously, as directed by a doctor, to treat any child. Children have a much greater response to topical steroid medications.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

Your chance of developing a kidney stone is 1 in 10. In recent years, approximately 3.7 million people in the United States were diagnosed with a kidney disease.

For a complete list of videos, visit our video library